Maryland 2024 Regular Session

Maryland House Bill HB411

Introduced
1/18/24  
Refer
1/18/24  
Report Pass
3/16/24  
Engrossed
3/18/24  
Refer
3/18/24  
Report Pass
4/1/24  
Enrolled
4/4/24  
Chaptered
5/16/24  

Caption

Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs

Impact

The enactment of HB 411 will have significant implications for state health laws concerning opioid abuse and management. By ensuring that patients have the option to choose among various formulations of opioid reversal drugs, the bill seeks to increase the effectiveness of interventions aimed at reversing overdoses. This change aligns with broader public health strategies focused on combating the opioid epidemic by removing barriers to accessing critical medical assistance.

Summary

House Bill 411, concerning public health, mandates that licensed healthcare providers allow individuals to choose from any formulation of FDA-approved opioid reversal drugs when issuing standing orders. The legislation aims to enhance the accessibility of these lifesaving medications in response to the ongoing opioid crisis. Additionally, the Maryland Department of Health is required to report to legislative committees on the current status of opioid reversal drugs and any standing orders in place on a set schedule.

Sentiment

The sentiment surrounding the bill appears to be largely positive among healthcare professionals and advocates for public health. Proponents argue that the flexibility in choosing formulations will ultimately save lives and enhance the effectiveness of treatment for opioid overdoses. There has been a concerted effort from various stakeholders, including the Maryland Department of Health, to support this initiative as a necessary step toward protecting vulnerable populations.

Contention

Although the bill has received strong support, some concerns have been raised regarding the potential implications of allowing flexibility for healthcare providers in issuing standing orders. Questions about the adequacy of training and awareness among providers regarding the various opioid reversal drugs available could lead to inconsistencies in treatment. Furthermore, criticisms may arise around ensuring that all patients receive the same quality of care regardless of their location or provider.

Companion Bills

MD SB408

Crossfiled Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs

Similar Bills

KY HB422

AN ACT relating to administrative regulations.

KY HB6

AN ACT relating to administrative regulations and declaring an emergency.

KY SB20

AN ACT relating to administrative regulations and declaring an emergency.

KY SB23

AN ACT relating to administrative regulations and declaring an emergency.

KY HB81

AN ACT relating to governmental accountability and declaring an emergency.

KY SB65

AN ACT relating to deficient administrative regulations and declaring an emergency.

KY HB594

AN ACT relating to administrative regulations and declaring an emergency.

KY HB40

AN ACT relating to administrative regulations and declaring an emergency.